Ticagrelor
Ticagrelor is a medication designed to prevent dangerous blood clots by inhibiting platelet aggregation. It is commonly associated with originator brands like Brilinta and Brilique. This page features 1 generic formulation relevant for long-term health management. It addresses complications related to cardiovascular function and is used specifically for Acute Coronary Syndrome.
Key points
- An antiplatelet medicine that targets the P2Y12 receptor on platelets to stop them clumping into clots.
- Unlike some other antiplatelet drugs, its effect wears off quickly once stopped, letting normal clotting ability return sooner.
- Should be avoided in people with active bleeding or a past intracranial haemorrhage, given the bleeding risk involved.
What is Ticagrelor?
Ticagrelor is an antiplatelet agent. It belongs to a specific class of medicines that prevent platelets from clumping together to form clots within the bloodstream. Managing conditions within the Heart & Blood Pressure category often requires consistent antiplatelet therapy to minimise risks.
This medication is intended for individuals who require long-term prevention of cardiac events. By keeping blood platelets from adhering to vessel walls, the compound reduces the likelihood of arterial blockages that can lead to severe health episodes.
What Ticagrelor is used for
Ticagrelor is used for patients with Acute Coronary Syndrome to prevent major cardiovascular events such as heart attack or stroke. It maintains clear blood flow in people who have recently experienced a cardiac event or are at high risk of arterial blockages.
The treatment focuses on reducing the incidence of blood-related obstructions in the coronary arteries. By adhering to a steady regimen of this medication, individuals manage the long-term risk of recurring vascular issues.
How does Ticagrelor work?
Platelets are blood cells that naturally clump together to stop bleeding. Ticagrelor identifies and blocks the P2Y12 receptor on these cells. By binding to this receptor, it prevents the chemical signals that normally trigger clumping, keeping blood flowing smoothly through the vessels.
This mechanism provides a rapid and reversible effect on the platelets. Unlike some other antiplatelet agents, the body recovers its natural clotting ability more quickly once the medication is stopped, provided the prescribed regimen is followed correctly.
Ticagrelor brands and forms
Products like Brilinta and Brilique are standard for this active compound. Depending on your needs, you may find the medicine typically provided as a film-coated tablet. These formulations ensure steady absorption into your bloodstream.
Safety overview for Ticagrelor
What to check before using this medicine
Avoid using this medicine if you have active pathological bleeding or a history of intracranial haemorrhage. Inform your doctor about all current medications, especially blood thinners or recent surgical procedures, as these impact how the body reacts to Ticagrelor.
Possible reactions and tolerability
Common reactions may include shortness of breath or minor bruising during daily activity. More severe issues involve unexpected bleeding that does not stop easily or signs of an allergic reaction.
Interactions and health factors
Interaction occurs with certain medications filtered by the liver or other antiplatelet agents. Your health history regarding liver function and gastrointestinal issues like peptic ulcers is relevant. Product labelling and verified clinical sources remain the correct references for specific contraindications, interactions and reactions.